The utility of ground-glass attenuation score for anticancer treatment-related acute exacerbation of interstitial lung disease among lung cancer patients with interstitial lung disease

AbstractBackgroundAcute exacerbation (AE) of interstitial lung disease (ILD) is a fatal adverse event in the treatment of lung cancer patients with ILD. The value of pre-treatment radiological findings obtained by high-resolution computed tomography for the detection of anticancer treatment-related AE of ILD has not been established.MethodsTwo medical record-based retrospective studies were performed. The chemotherapy cohort included 105 lung cancer patients with ILD who received chemotherapy at Tokyo Medical and Dental University between October 2008 and December 2017. The immune checkpoint inhibitor (ICI) cohort included 48 advanced non-small cell lung cancer patients with ILD treated with ICIs at nine institutions between January 2016 and September 2018. Variables were compared between AE-positive and -negative groups. Candidate variables were analyzed by multivariate logistic regression. AP value  
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

AbstractThe safety of anti-programmed cell death 1 (PD-1) antibody for patients with preexisting interstitial lung disease (ILD) remains unknown. The aim of this study was to evaluate the dependence of preexisting ILD on anti-PD-1 antibody-induced pneumonitis in non-small cell lung cancer (NSCLC) patients. We retrospectively reviewed the association of preexisting ILD with the incidence, radiographic pattern, and outcome of pneumonitis in NSCLC patients receiving anti-PD-1 antibody. A total of 331 patients were included in this study. Of these patients, 17 had preexisting ILD. The incidence of pneumonitis was higher among ...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
Conclusion: The treatment with pemetrexed plus platinum has a high risk of AE-ILD in patients with advanced nonsquamous NSCLC and preexisting ILD.
Source: In Vivo - Category: Research Authors: Tags: Clinical Studies Source Type: research
ConclusionsThis is the first prospective phase II trial of weekly nabPTX in combination with CBDCA in advanced NSCLC patients with ILD. This treatment showed favorable efficacy and was well tolerated.Clinical trial identificationUMIN000012901.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureT. Harada: Honoraria (institution): GlaxoSmithKline K.K.; Honoraria (institution): Hisamitsu Pharmaceutical Co.,Inc; Honoraria (institution): Boehrnger INgelheim. S. Oizumi: Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Chugai Pharmace...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsPatients with NSCLC with these factors for poor prognosis of nivolumab-induced ILD should be monitored for ILD during nivolumab treatment.Editorial acknowledgementMedical writing assistance was provided by Justine Southby, PhD, CMPP, and Hiroko Ebina, BPharm, Ph, MBA, of ProScribe – Envision Pharma Group, and was funded by Ono Pharmaceutical Co., Ltd.Legal entity responsible for the studyOno Pharmaceutical Co., Ltd.FundingOno Pharmaceutical Co., Ltd., Osaka, Japan, and Bristol-Myers Squibb K.K., Tokyo, Japan.DisclosureK. Oikado: Honoraria (self): Ono Pharmaceutical ; Honoraria (self): AstraZeneca. Y. Saito...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Lung cancer is the leading cause of cancer-related death worldwide, and non-small cell lung cancer (NSCLC) accounts for more than 80% of all such cancers [1]. Drugs that target specific molecular abnormalities within the tumor, such as EGFR mutations, ALK rearrangements, ROS1 rearrangements, and BRAF mutations are the preferred first-line therapies for patients with adenocarcinoma [2]. Immune checkpoint inhibitors (ICIs) with or without cytotoxic chemotherapy are also effective. Pembrolizumab monotherapy; pembrolizumab and platinum-based doublet combination; and atezolizumab, bevacizumab, and platinum-based doublet combina...
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
The safety of treatment with immune ‐checkpoint inhibitors prior to thoracic surgery in patients with non‐small cell lung cancer (NSCLC) remains unclear. Here, we describe the case of a 62‐year‐old woman with NSCLC with programmed death ligand 1 expression on 85% of tumor cells. The patient was initially considered to have unr esectable stage IIIB disease and received pembrolizumab monotherapy. After 12 cycles of pembrolizumab, the primary tumor was reduced, but a small lung nodule in another lobe was unchanged. Based on the course of image findings, the nodule was considered to be an old inflammatory change...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: CASE REPORT Source Type: research
ConclusionCIP is a serious complication with a poor prognosis associated with high mortality. The efficacy of ICI is significantly worse in patients with severe grade CIP than in those without severe grade CIP. Whether ICIs should be administered to patients with CIP risk factors, such as an ECOG PS score of ≥2 or pre‐existing ILD, should be carefully assessed.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Conclusion.This S‐1 and PTX cotherapy dose and schedule showed satisfactory efficacy, with mild toxicities, in patients with previously treated advanced NSCLC.
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Lung Cancer, Chinese Edition, Clinical Trial Results Source Type: research
Rationale: Pembrolizumab, an immune-checkpoint inhibitor (ICI), has been shown to be effective for treatment-naive patients with non–small cell lung cancer (NSCLC) and high expression of programmed death-ligand 1 (PD-L1). Therefore, treatment regimens containing pembrolizumab have become a standard therapy for these patients. However, the use of pembrolizumab is limited owing to the side effects of ICIs. Patient concerns and diagnoses: The patient was a 65-year-old man with a left lung mass surrounded by interstitial shadow. The tumor was diagnosed as adenocarcinoma, cT4N3M0, stage IIIC, and the tumor cells show...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | CT Scan | Interstitial Lung Disease | Lung Cancer | Non-Small Cell Lung Cancer | Statistics | Study